Kallisio’s Stentra wins CE mark for head and neck RT system

Kallisio said its Stentra intraoral positioning system has received CE certification under the European Union’s Medical Device Regulation, allowing commercial sale across the European Economic Area. The device is a patient-specific, 3D-printed oral stent used during external beam radiation therapy to repeatedly position and immobilize the tongue and jaw, helping move healthy oral structures away from the treatment field. The company had previously received U.S. FDA 510(k) clearance for Stentra, and says the system is designed to fit into existing radiation oncology workflows without changes to treatment-planning software or IT infrastructure. (medicaleconomics.com)

Why it matters: For veterinary professionals, this is a human oncology regulatory milestone worth watching because it reflects continued movement toward patient-specific immobilization and displacement tools in radiation therapy. In both human and veterinary settings, reproducible positioning matters for dose accuracy, normal-tissue sparing, and workflow efficiency, especially in head and neck cases where small setup differences can affect organs at risk. Kallisio says Stentra can be delivered within 72 hours and may be reimbursable under existing CPT pathways in human care, which could help support broader adoption of similar customized devices over time. (accessdata.fda.gov)

What to watch: Watch for early European commercial rollout, pilot-site uptake, and any published clinical outcomes on whether patient-specific oral stents reduce toxicities such as oral mucositis in routine practice. (medicaleconomics.com)